Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
Loss of function variant in FLT3 strongly increases the risk of autoimmune thyroid disease and other autoimmune diseases
The combination of genomics, transcriptomics and proteomics sheds light on autoimmune thyroid disease, other autoimmune diseases and AML
Archaic genetic fragments comprising nearly half the Neanderthal genome are circulating in the European gene pool today.
The average European carries more than 500 such archaic fragments, including SNPs linked to prostate cancer risk, iron retention, blood clotting speed, and height
Award by the American Society of Human Genetics
At its Annual meeting in October 2017 in Orlando, the American Society of Human Genetics (ASHG), presented Dr. Kári Stefánsson, founder and CEO of deCODE genetics, with the William Allan Award. The award, the top prize given by the society, recognizes a scientist for substantial and far-reaching scientific contributions to human genetics. The ASHG has distributed video footage from the award ceremony. The introduction is given by Professor Mark Daly of Harvard University.